NPM1 and acute myeloid leukemia: The screening of a large cohort of 2426 NPM1-mut AML patients negative for FLT3-ITD or with a low FLT3-ITD allelic ratio (NPM1-mut/FLT3-ITDneg/low) showed that 17.6% of these patients displayed an abnormal karyotype: 13.6% of patients had intermediate-risk and 3.4% had adverse-risk chromosomal abnormalities [8].